Both Sides of the Table
JANUARY 26, 2013
Understanding “The Funding Angle” I sit at enough board meetings to hear conflicting advice given to entrepreneurs about how to handle PR and announcements at startups. Is Funding a Worthy Announcement? There are reasons you may delay funding announcement but rarely reasons not to announce. But trust me on this.
TechCrunch LA
JUNE 18, 2022
Last week, we talked about layoffs and the Winklevoss rock gods. Molecule , a platform where DAOs can back medical research projects, secured $13 million in seed funding led by Northpond Ventures. Decentralized trading infrastructure startup Orderly Network raised $20 million in Series A funding from investors including ??Three
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Xconomy
OCTOBER 7, 2016
The firm will now focus on its miniLab, which CEO Elizabeth Holmes touted as a follow-on version of its Edison test system at a scientific conference in August. The funding could be as much as $100 million, and the first grants will be announced in 2017. She refused to discuss Edison at the time. —The U.S. THE ENVELOPE, PLEASE.
Both Sides of the Table
JANUARY 22, 2013
” That way you aren’t hitting him up on an important topic when he might be stressed out about company layoffs, fund raising or some other major stress at work. He usually says no to weekend conferences and events. He can then find a calm time for a heavy conversation that is planned in advance.
Xconomy
JUNE 17, 2016
Data from a hematology conference stoked dreams of approval, though still on a far horizon, for a couple drug makers. Familiar biotech names—not necessarily familiar for the right reasons—made news this week in biotech. Long anticipated, Walgreens officially cut ties with Theranos , and the FDA both gave and denied approvals.
Xconomy
JULY 15, 2016
All eyes are on Holmes, who is scheduled to present data from the company’s technology at a medical conference on August 1. million in funding, according to a regulatory filing. It would be the first time Theranos has shared data with the world. A UCSF cancer expert called XBiotech’s data release “bogus.”
Expert insights. Personalized for you.
355 
Let's personalize your content